AI
SCLN

Analytic Investors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Analytic Investors’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$803K Buy
+78,322
New +$853K 0.01% 403
2015
Q1 		– Sell
-54,216
Closed -$475K – 639
2014
Q4 		$475K Buy
+54,216
New +$439K 0.01% 426

Other funds holding SCLN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Analytic Investors's SCLN Position: Q3 2016 in Review

Analytic Investors opened a new position in Sciclone Pharmaceuticals Inc (SCLN) in Q3 2016: 78,322 shares worth $803K. The stake represents 0.01% of the portfolio and ranks #403 among its holdings. This is a return to the name: Analytic Investors previously reported a position in SCLN as recently as Q4 2014.

Analytic Investors first reported a position in SCLN in Q4 2014 and has held it in 2 quarters since. 152 funds tracked by Wall St. Rank hold SCLN as of Q3 2016.

  • Analytic Investors held 78,322 shares of Sciclone Pharmaceuticals Inc worth $803K as of Q3 2016.
  • Sciclone Pharmaceuticals Inc was a new Analytic Investors position in Q3 2016.
  • Sciclone Pharmaceuticals Inc made up 0.01% of Analytic Investors's portfolio in Q3 2016, its #403 holding.
  • Analytic Investors first reported a position in Sciclone Pharmaceuticals Inc in Q4 2014 and has held it in 2 quarters since.
  • 152 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2016.

Based on Analytic Investors's 13F filing for Q3 2016, filed 14 Nov 2016.